نتایج جستجو برای: alteplase

تعداد نتایج: 6831  

Journal: :Stroke 2017
Connor Batchelor Pooneh Pordeli Christopher D d'Esterre Mohamed Najm Fahad S Al-Ajlan Mari E Boesen Connor McDougall Lisa Hur Enrico Fainardi Jai Jai Shiva Shankar Marta Rubiera Alexander V Khaw Michael D Hill Andrew M Demchuk Tolulope T Sajobi Mayank Goyal Ting-Yim Lee Richard I Aviv Bijoy K Menon

BACKGROUND AND PURPOSE Intracerebral hemorrhage is a feared complication of intravenous alteplase therapy in patients with acute ischemic stroke. We explore the use of multimodal computed tomography in predicting this complication. METHODS All patients were administered intravenous alteplase with/without intra-arterial therapy. An age- and sex-matched case-control design with classic and cond...

Journal: :Stroke 2008
Hans-Christoph Diener Kennedy R Lees Patrick Lyden Jim Grotta Antoni Davalos Stephen M Davis Ashfaq Shuaib Tim Ashwood Warren Wasiewski Vivian Alderfer Hans-Goran Hårdemark Larry Rodichok

BACKGROUND AND PURPOSE In animal models of acute ischemic stroke (AIS), the free radical-trapping agent NXY-059 showed promise as a neuroprotectant. SAINT I and II were randomized, placebo-controlled, double-blind trials to investigate the efficacy of NXY-059 in patients with AIS. METHODS Patients with AIS received an infusion of intravenous NXY-059 or placebo within 6 hours from the onset of...

2014
Masatoshi Koga Kazunori Toyoda Kazumi Kimura Haruko Yamamoto Makoto Sasaki Toshimitsu Hamasaki Takanari Kitazono Junya Aoki Kenta Seki Kazunari Homma Shoichiro Sato Kazuo Minematsu

RATIONALE Because of lack of information regarding timing of stroke, patients who suffer stroke during sleep are generally ineligible for intravenous thrombolysis, although many of these patients could potentially recover with this treatment. Magnetic resonance image findings with positive diffusion-weighted imaging and no marked parenchymal hyperintensity on fluid-attenuated inversion recovery...

Journal: :Circulation 2001
M P Hudson C B Granger E J Topol K S Pieper P W Armstrong G I Barbash A D Guerci A Vahanian R M Califf E M Ohman

BACKGROUND Trials report a 2% to 6% incidence of reinfarction after fibrinolysis for acute myocardial infarction (MI). We combined the Global Utilization of Streptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries (GUSTO I) and Global Use of Strategies To Open occluded coronary arteries (GUSTO III) populations to better define frequency, timing, and clinical pre...

Journal: :Stroke 2008
Paul A Lapchak Moon-Ku Han Karmen F Salgado Jackson Streeter Justin A Zivin

BACKGROUND AND PURPOSE Transcranial near-infrared laser therapy (TLT) is currently under investigation in a pivotal clinical trial that excludes thrombolytic therapy. To determine if combining tissue plasminogen activator (tPA; Alteplase) and TLT is safe, this study assessed the safety profile of TLT administered alone and in combination with Alteplase. The purpose for this study is to determin...

Journal: :Stroke 2011
Roberto Muñoz Arrondo Laura Pulido Fontes Jaime Gállego Culleré

BACKGROUND AND PURPOSE Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been reported in the second Interventional Management of Stroke (IMS 2) trial with contrast toxicity potentially contributory. METHODS We reviewed clinical and ra...

2006
Takenori Yamaguchi Etsuro Mori Kazuo Minematsu Jyoji Nakagawara Isamu Saito

Background and Purpose—Based on previous studies comparing different recombinant tissue plasminogen activator (rt-PA) doses, we performed a clinical trial with 0.6 mg/kg, which is lower than the internationally approved dosage of 0.9 mg/kg, aiming to assess the efficacy and safety of alteplase in acute ischemic stroke for the Japanese. Methods—Our prospective, multicenter, single-arm, open-labe...

Journal: :European heart journal 2003
Lars Wallentin Lott Bergstrand Mikael Dellborg Carin Fellenius Christopher B Granger Bertil Lindahl Lars Eric Lins Tage Nilsson Kenneth Pehrsson Agneta Siegbahn Eva Swahn

BACKGROUND Current thrombolytic-antithrombotic regimens in acute myocardialinfarction (AMI) are limited by incomplete early coronary reperfusion and by reocclusion and reinfarction. We compared the effects of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) as an adjunct to recombinant tissue-plasminogen activator (alteplase) on coronary artery patency and clinical outcom...

2017
Lily Song Xia Wang Thompson Robinson Richard I Lindley Hisatomi Arima Pablo M Lavados Xiaoying Chen John Chalmers Craig S Anderson

BACKGROUND The characteristics of patients with acute ischaemic stroke (AIS) and their management vary across regions, which may influence outcomes. We examined for differential patterns of outcome between China and non-China participants of the ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED), which tested different alteplase doses in AIS. METHODS ENCHANTED was an i...

Journal: :Chest 2004
Venu Menon Robert A Harrington Judith S Hochman Christopher P Cannon Shaun D Goodman Robert G Wilcox Holger J Schünemann E Magnus Ohman

This chapter about antithrombotic therapy for acute myocardial infarction (MI) is part of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید